Ropinirole is a medication used in this trial to help manage symptoms of Restless Legs Syndrome (RLS). It works by mimicking the action of dopamine, a natural substance in the brain that helps control movement. This medication is often used to improve sleep and reduce discomfort in the legs, which can be particularly beneficial for women with X-linked Adrenoleukodystrophy (ALD) experiencing RLS.

X-linked adrenoleukodystrophy – This is a genetic disorder that affects the nervous system and adrenal glands. It is caused by mutations in the ABCD1 gene, leading to the accumulation of very long-chain fatty acids in the body. The disease primarily affects males and can lead to a range of neurological symptoms. These symptoms may include muscle stiffness, weakness, and problems with coordination. Over time, individuals may experience progressive neurological decline. The severity and progression can vary widely among those affected.

Restless legs syndrome – This is a condition characterized by an uncontrollable urge to move the legs, usually due to uncomfortable sensations. It typically occurs in the evening or nighttime hours when a person is sitting or lying down. Moving the legs often provides temporary relief from the discomfort. The sensations can range from mild to severe and may disrupt sleep. The exact cause is not fully understood, but it may involve an imbalance of dopamine in the brain. The condition can affect daily activities and quality of life.